	US 11,919,945 B2
	Neutralizing anti-SARS-CoV-2 antibodies
Michel Nussenzweig, New York, NY (US)
Assigned to The Rockefeller University, New York, NY (US)
Filed by The Rockefeller University, New York, NY (US)
Filed on Nov. 4, 2021, as Appl. No. 17/519,173.
Claims priority of provisional application 63/109,567, filed on Nov. 4, 2020.
Prior Publication US 2022/0195015 A1, Jun. 23, 2022
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); A61K 39/42 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/10 (2013.01) [A61K 39/42 (2013.01); A61P 31/14 (2018.01); G01N 33/56983 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/165 (2013.01)]

33 Claims

1. An isolated anti-SARS-CoV-2 antibody or antigen-binding fragment thereof that binds specifically to a SARS-CoV-2 antigen, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising respective amino acid sequences of (a) SEQ ID NOs: 4600, 4601, 4602, 4603, 4604, and 4605; (b) SEQ ID NOs: 4606, 4607, 4608, 4609, 4610, and 4611; (c) SEQ ID Nos: 4612, 4613, 4614, 4615, 4616, and 4617; (d) SEQ ID NOs: 4618, 4619, 4620, 4621, 4622, and 4623; (e) SEQ ID NOs: 4624, 4625, 4626, 4627, 4628, and 4629; (f) SEQ ID NOs: 4630, 4631, 4632, 4633, 4634, and 4635; (g) SEQ ID NOs: 4642, 4643, 4644, 4645, 4646, and 4647; (h) SEQ ID NOs: 4648, 4649, 4650, 4651, 4652, and 4653; (i) SEQ ID NOs: 4654, 4655, 4656, 4657, 4658, and 4659; or (j) SEQ ID NOs: 4660, 4661, 4662, 4663, 4664, and 4665.